Drug resistance in colon cancer

R. Gorlick, J. R. Bertino

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.

Original languageEnglish (US)
Pages (from-to)606-611
Number of pages6
JournalSeminars in Oncology
Volume26
Issue number6
StatePublished - 1999
Externally publishedYes

Fingerprint

Drug Resistance
Colonic Neoplasms
Pharmaceutical Preparations
Colorectal Neoplasms
Drug Therapy
DNA Repair
DNA Damage
Stomach
Cell Cycle
Clinical Trials
Genes
raltitrexed

ASJC Scopus subject areas

  • Oncology

Cite this

Gorlick, R., & Bertino, J. R. (1999). Drug resistance in colon cancer. Seminars in Oncology, 26(6), 606-611.

Drug resistance in colon cancer. / Gorlick, R.; Bertino, J. R.

In: Seminars in Oncology, Vol. 26, No. 6, 1999, p. 606-611.

Research output: Contribution to journalArticle

Gorlick, R & Bertino, JR 1999, 'Drug resistance in colon cancer', Seminars in Oncology, vol. 26, no. 6, pp. 606-611.
Gorlick R, Bertino JR. Drug resistance in colon cancer. Seminars in Oncology. 1999;26(6):606-611.
Gorlick, R. ; Bertino, J. R. / Drug resistance in colon cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 6. pp. 606-611.
@article{1404fe41a627446b85a3abd0cff98af9,
title = "Drug resistance in colon cancer",
abstract = "A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.",
author = "R. Gorlick and Bertino, {J. R.}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "606--611",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Drug resistance in colon cancer

AU - Gorlick, R.

AU - Bertino, J. R.

PY - 1999

Y1 - 1999

N2 - A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.

AB - A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.

UR - http://www.scopus.com/inward/record.url?scp=0033400231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033400231&partnerID=8YFLogxK

M3 - Article

C2 - 10606253

AN - SCOPUS:0033400231

VL - 26

SP - 606

EP - 611

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -